This issue of Obstetrics and Gynecology Clinics of North America deals with the timely subject of substance use during pregnancy. Alcohol, tobacco, and illicit drug use is prevalent among reproductive-age women. Even though a reduction in use often occurs during pregnancy, many women continue to use substances until a pregnancy is either actually diagnosed or well underway.This issue consists of a well-qualified team of obstetricians-gynecologists, psychiatrists, and family physicians, focusing on various issues related directly to pregnancies complicated by substance use. Topics of interest include epidemiology and screening for hazardous and harmful substance use, teratogenic risks, psychiatric comorbidities, comprehensive treatment approaches before and after delivery, fetal surveillance, and team-based perinatal management. Particularly new information relates to prescribing buprenorphine, neonatal abstinence syndrome, and adolescent substance use.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 5 6. Foreword - p. 6 7. Preface - p. 7 8. Epidemiology of Substance Use in Reproductive-Age Women - p. 8 9. Adolescent Substance Use and Unplanned Pregnancy - p. 15 10. Screening for Alcohol and Drug Use During Pregnancy - p. 23 11. Prenatal and Postpartum Care of Women with Substance Use Disorders - p. 28 12. Teratogenic Risks from Exposure to Illicit Drugs - p. 38 13. Buprenorphine and Methadone for Opioid Addiction During Pregnancy - p. 45 14. Smoking Cessation in Pregnancy - p. 53 15. Substance Abuse Treatment Services for Pregnant Women - p. 60 16. The Perils of Opioid Prescribing During Pregnancy - p. 74 17. Fetal Surveillance in Late Pregnancy and During Labor - p. 80 18. Neonatal Opioid Withdrawal Syndrome - p. 85 19. Index - p. 95
No hay muestra disponible
No hay ficha técnica disponible
This issue of Obstetrics and Gynecology Clinics of North America deals with the timely subject of substance use during pregnancy. Alcohol, tobacco, and illicit drug use is prevalent among reproductive-age women. Even though a reduction in use often occurs during pregnancy, many women continue to use substances until a pregnancy is either actually diagnosed or well underway.This issue consists of a well-qualified team of obstetricians-gynecologists, psychiatrists, and family physicians, focusing on various issues related directly to pregnancies complicated by substance use. Topics of interest include epidemiology and screening for hazardous and harmful substance use, teratogenic risks, psychiatric comorbidities, comprehensive treatment approaches before and after delivery, fetal surveillance, and team-based perinatal management. Particularly new information relates to prescribing buprenorphine, neonatal abstinence syndrome, and adolescent substance use.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 5 6. Foreword - p. 6 7. Preface - p. 7 8. Epidemiology of Substance Use in Reproductive-Age Women - p. 8 9. Adolescent Substance Use and Unplanned Pregnancy - p. 15 10. Screening for Alcohol and Drug Use During Pregnancy - p. 23 11. Prenatal and Postpartum Care of Women with Substance Use Disorders - p. 28 12. Teratogenic Risks from Exposure to Illicit Drugs - p. 38 13. Buprenorphine and Methadone for Opioid Addiction During Pregnancy - p. 45 14. Smoking Cessation in Pregnancy - p. 53 15. Substance Abuse Treatment Services for Pregnant Women - p. 60 16. The Perils of Opioid Prescribing During Pregnancy - p. 74 17. Fetal Surveillance in Late Pregnancy and During Labor - p. 80 18. Neonatal Opioid Withdrawal Syndrome - p. 85 19. Index - p. 95
No hay muestra disponible
No hay ficha técnica disponible
